NCT00101400已完成2 期
A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Subjects With Metastatic Breast Cancer.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 54
- 主要终点
- Number of Subjects With Response (Complete or Partial)
研究概览
简要总结
The purpose of this study is to evaluate the anti-cancer activity and safety of BAY43-9006 (Sorafenib) in patients, who suffer from an advanced breast tumour, which has spread to other organs of body despite treatment that the patient has received so far.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years
- •Women with prior histologically documented diagnosis of breast cancer
- •Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and, if ER/PgR +ve, have failed on at least adjuvant hormonal therapy
- •Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects
- •Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy
- •Subjects who have at least one measurable lesion by CT (Computed Tomography) scan or MRI (Magnetic Resonance Imaging) according to modified WHO Tumour Response Criteria
- •Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory evaluations:
- •Hemoglobin > 9.0 g/dl
- •Absolute neutrophil count (ANC) > 1,500/mm3
- •Platelet count = 100,000/µl
- •Total bilirubin =1.5 x the upper limit of normal.
- •Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5 x upper limit of normal (=5 x upper limit of normal for subjects with liver involvement of their cancer)
- •Amylase and lipase = 1.5 x the upper limit of normal
- •Serum creatinine = 3.0 x the upper limit of normal
- •Prothrombin Time (PT) or International Normalized Ratio (INR) and Partial Thromboplastin Time (PTT) < 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists)
- •Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice
- •Life expectancy of at least 12 weeks
- •Signed informed consent must be obtained prior to any study specific procedures
排除标准
- •Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumours [Ta, Tis and T1] or other malignancies curatively treated > 2 years prior to entry)
- •Congestive heart failure > New York Heart Association (NYHA) Class II
- •Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin)
- •Active coronary artery disease or ischaemia
- •Active clinically serious bacterial or fungal infections (> grade 2 National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3)
- •Known History of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or C
- •Metastatic brain or meningeal tumors unless the subject is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study)
- •Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics)
- •History of organ allograft
- •Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
- •Known or suspected allergy to the investigational agent
- •Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.
- •Excluded therapies include:
- •Anti-cancer chemotherapy, hormonal therapy or immunotherapy during the study or within 4 weeks of study entry. Mytomicin or nitroureas should not be given within 6 weeks of study entry
- •Significant surgery within 4 weeks prior to the start of study drug
- •Any bone marrow transplant or stem cell rescue within 4 months of the start of study drug
- •Radiotherapy during the study or within 3 weeks of the start of drug
- •Use of biologic response modifiers, such as Granulocyte-Colony Stimulating Factor (G-CSF), within 3 weeks of study entry
- •Investigational drug therapy outside of this trial during or within 30 days prior to start of the study drug
- •Concomitant treatment with ketoconazole, itraconazole, ritonavir, or use of grapefruit juice
- •Prior use of Raf-Kinase Inhibitors (RKI), Methyl Ethyl Ketone (MEK) or farnesyl transferase inhibitors
- •Concomitant treatment or use of St. John's Wort
- •Prior use of bevacizumab and all other drugs that target Vascular Endothelial Growth Factor (VEGF)/VEGF receptors
研究组 & 干预措施
Sorafenib (Nexavar, BAY43-9006)
Experimental
Sorafenib 400 mg administered twice daily (b.i.d.)
干预措施: Sorafenib (Nexavar, BAY43-9006) (Drug)
结局指标
主要结局
Number of Subjects With Response (Complete or Partial)
时间窗: Until 30 days after termination of active therapy
Number of subjects with metastatic breast cancer treated with single agent BAY43-9006 who had best overall response assessed as complete response (CR) or partial response (PR) as per Modified World Health Organization (WHO) Tumor Response Criteria.
次要结局
- Overall Response Duration(Time from PR or CR to progression)
- Survival Time(Start of treatment to death)
- Time to Objective Response(Until objective response occurs)
- Number of Subjects With Stable Disease up to Cycle 4(Until 30 days after termination of active therapy)
- Time to Progression(Until progression occurs)
研究者
相似试验
已完成
2 期
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)Carcinoma, Non-Small Cell LungCancerNCT00101413Bayer52
已完成
2 期
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic MelanomaMelanomaNCT00492297Bayer83
已完成
2 期
Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to GleevecChronic Myelogenous LeukemiaNCT00661180Bayer10
已完成
2 期
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate CancerProstate CancerNCT00090545National Cancer Institute (NCI)46
已完成
2 期
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerRecurrent Ovarian CarcinomaPrimary Peritoneal CarcinomaNCT00093626National Cancer Institute (NCI)73